Evidence map›Paper›PMID 42653893›Full record

ArticleMolecules (Basel, Switzerland)2026

Development and Validation of a Method to Determine CYP4V2 Enzyme Activity in rAAV-hCYP4V2 Gene Therapy Products Using a Bioluminescent Substrate Assay.

Yiran Li, Wenhong Fan, Shuting Hou, Yue Ding, Xiuqing Jia, Xi Zhu, Yuemeng Yuan, Yufei Zhang, Yanrong Cao, Xi Qin and 2 more

Abstract readValidation Study
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yiran LiNational Institutes for Drug Control, Beijing 100050, China.ORCID 0009-0009-1884-4440
Wenhong FanNational Institutes for Drug Control, Beijing 100050, China.
Shuting HouNational Institutes for Drug Control, Beijing 100050, China.
Yue DingNational Institutes for Drug Control, Beijing 100050, China.
Xiuqing JiaNational Institutes for Drug Control, Beijing 100050, China.
Xi ZhuShanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Yuemeng YuanShanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Yufei ZhangShanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Yanrong CaoShanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Xi QinNational Institutes for Drug Control, Beijing 100050, China.
Chenggang LiangNational Institutes for Drug Control, Beijing 100050, China.ORCID 0000-0001-8916-6872
Lan WangNational Institutes for Drug Control, Beijing 100050, China.

Funding

National Institutes for Drug Control Z251100004625002,2025SKLDRS0354
6 · The paper itself

Abstract

Bietti crystalline dystrophy like retinal degeneration (BCD) is an inherited retinal degenerative disease caused by defects in the CYP4V2 gene. Recombinant AAV-based gene replacement therapy holds promise for this disease, yet reliable enzymatic activity assays for product potency evaluation remain urgently needed. This study established and validated a method for determining the enzymatic activity of CYP4V2 based on the bioluminescent substrate Luciferin-MultiCYP.HEK293-AAVR cells were seeded at 1 × 10

Indexed as

Cytochrome P450 Family 4DependovirusGenetic TherapyLuminescent MeasurementsRetinal DiseasesCorneal Dystrophies, HereditaryGene Therapy AgentsGenetic VectorsHEK293 CellsHumansReproducibility of ResultsCytochrome P450 Family 4adeno-associated virusbioluminescent substrate methodCYP4V2enzyme activitygene therapymethod validation

Identifiers

PMID42653893
PMCPMC13515460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.